NCT04770623 - Docetaxel and Irinotecan in Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Stomach CancerGastric CancerChemotherapy Effect

Interventions

DRUG

Docetaxel

patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival

DRUG

Irinotecan

patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival

Trial Locations (1)

32511

Menoufia University, Faculty of medicine, Shibīn al Kawm

All Listed Sponsors

lead

Menoufia University

OTHER